Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Debate At PSA 2013: Can ‘Dream Team’ Approach To Scientific Innovation Work for Big Pharma?

This article was originally published in The Pink Sheet Daily

Executive Summary

How best to tap scientific innovation? Identifying the top ‘true’ innovators and nurturing them and their ideas in-house may work for biotechs like Regeneron, but the fruits of such efforts are too rare to be reliable growth engines for big companies like Pfizer. That’s one takeaway from a lively R&D chiefs debate at Elsevier’s PSA 2013.

You may also be interested in...



Regeneron/Sanofi’s Long-Term Alliances Begin Bearing Fruit

Regeneron’s five-year-old antibody partnership with Sanofi may be expensive, but it is starting to produce some interesting compounds in mid-to-late-stage clinical trials, with positive data to show.

Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond

The better-than-expected performance of Regeneron’s first significant commercial drug, Eylea, has fueled the company’s ambitions to build a sustainable, risk-adjusted portfolio based on a mix of best-in-class and first-in-class new drugs. Getting to this point took a mixture of perseverance, astute science, opportunism, and savvy partnering.

Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment

ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?

Topics

Related Companies

UsernamePublicRestriction

Register

PS076295

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel